fostering a stronger commitment
to quality mindset delivering an across its operations. With a ownership key emphasis on experience. The ‘Fix It Right the First initiative reflects Time’, the initiative Nissan's belief that
CHENNAI – 8 Nov, 2026 National
Pharmaceutical
Pricing Authority (NPPA), under the Department of
Pharmaceuticals, Ministry of Chemicals and Fertilizers, capped trade margins on MRP of 137 anti-cancer drugs, based on the
recommendations of Expert Committee constituted by the Directorate General of Health Services (DGHS) under
Ministry of Health & Family Welfare on 17 th October, 2026. The revised prices of these drugs will come into effect from 9 th November, 2026.
As on date, 76 pharmaceutical
companies have reported revised MRP for 1225 anti-cancer formulations, covering 121 drugs. Reduction in the MRP have been reported in 1031 formulations of anti-cancer medicines, with 600 brands reporting above 50% reduction and the highest reduction being 96.45%.
Further, out of the 137 identified anti-cancer drugs, there are 10-15 drugs which are yet to be launched in India. However, Trade Margin Rationalization (TMR) will be applicable on these drugs also as and when they are launched.